DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China · Delayed Price · Currency is CNY 16.50
+0.25 (1.54%)
May 29, 2026, 3:00 PM CST
SHA:603233 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 26,862 | 26,845 | 25,861 | 23,931 | 20,780 | 16,759 |
Other Revenue | 657.1 | 657.1 | 635.56 | 599.94 | 467.67 | - |
| 27,519 | 27,502 | 26,497 | 24,531 | 21,248 | 16,759 | |
Revenue Growth (YoY) | 3.07% | 3.79% | 8.01% | 15.45% | 26.78% | 14.92% |
Cost of Revenue | 18,029 | 18,092 | 17,422 | 15,795 | 13,226 | 10,385 |
Gross Profit | 9,491 | 9,410 | 9,074 | 8,736 | 8,022 | 6,374 |
Selling, General & Admin | 7,234 | 7,215 | 7,424 | 6,808 | 6,270 | 5,187 |
Research & Development | 42.09 | 41.27 | 51.68 | 80.93 | 74.38 | 44.61 |
Other Operating Expenses | 126.4 | 105.23 | 35.47 | 35.32 | 64.57 | 29.94 |
Operating Expenses | 7,415 | 7,375 | 7,527 | 6,940 | 6,432 | 5,273 |
Operating Income | 2,076 | 2,036 | 1,547 | 1,796 | 1,590 | 1,101 |
Interest Expense | -171.44 | -189.38 | -248.83 | -239.26 | -231.97 | -212.04 |
Interest & Investment Income | 65.66 | 69.6 | 82.23 | 91.75 | 68.89 | 77.7 |
Currency Exchange Gain (Loss) | -0.7 | -0.7 | 0.32 | - | - | - |
Other Non Operating Income (Expenses) | -33.11 | -34.45 | -46.64 | -49.85 | -48.52 | -29.15 |
EBT Excluding Unusual Items | 1,937 | 1,881 | 1,335 | 1,599 | 1,379 | 937.76 |
Impairment of Goodwill | -53.58 | -53.58 | -38.6 | -6.21 | - | - |
Gain (Loss) on Sale of Investments | -5.45 | -1.52 | 10.61 | 4.38 | -18.71 | 34.57 |
Gain (Loss) on Sale of Assets | 18.04 | 14.7 | 19.21 | 3.43 | 18.73 | 5.63 |
Asset Writedown | 4.91 | - | - | - | - | - |
Other Unusual Items | 6.36 | 9.1 | 13.89 | 27.05 | 36.36 | 65.94 |
Pretax Income | 1,907 | 1,849 | 1,340 | 1,628 | 1,415 | 1,044 |
Income Tax Expense | 502.24 | 490.53 | 359.73 | 397.12 | 335.62 | 239.52 |
Earnings From Continuing Operations | 1,405 | 1,359 | 979.94 | 1,231 | 1,079 | 804.39 |
Minority Interest in Earnings | -118.42 | -123.67 | -65.19 | -64.16 | -43.55 | -13.16 |
Net Income | 1,286 | 1,235 | 914.75 | 1,166 | 1,036 | 791.23 |
Net Income to Common | 1,286 | 1,235 | 914.75 | 1,166 | 1,036 | 791.23 |
Net Income Growth | 31.76% | 35.04% | -21.58% | 12.63% | 30.90% | -25.51% |
Shares Outstanding (Basic) | 1,140 | 1,144 | 1,129 | 1,133 | 1,138 | 1,130 |
Shares Outstanding (Diluted) | 1,140 | 1,144 | 1,129 | 1,133 | 1,138 | 1,130 |
Shares Change (YoY) | 0.71% | 1.28% | -0.28% | -0.50% | 0.69% | -0.24% |
EPS (Basic) | 1.13 | 1.08 | 0.81 | 1.03 | 0.91 | 0.70 |
EPS (Diluted) | 1.13 | 1.08 | 0.81 | 1.03 | 0.91 | 0.70 |
EPS Growth | 30.84% | 33.33% | -21.36% | 13.19% | 30.00% | -25.33% |
Free Cash Flow | 4,037 | 4,865 | 1,626 | 1,377 | 2,722 | 260.05 |
Free Cash Flow Per Share | 3.54 | 4.25 | 1.44 | 1.22 | 2.39 | 0.23 |
Dividend Per Share | 0.830 | 0.830 | 0.620 | 0.310 | 0.500 | 0.347 |
Dividend Growth | 33.87% | 33.87% | 100.00% | -38.00% | 43.97% | -24.99% |
Gross Margin | 34.49% | 34.22% | 34.25% | 35.61% | 37.76% | 38.03% |
Operating Margin | 7.54% | 7.40% | 5.84% | 7.32% | 7.48% | 6.57% |
Profit Margin | 4.67% | 4.49% | 3.45% | 4.75% | 4.87% | 4.72% |
Free Cash Flow Margin | 14.67% | 17.69% | 6.14% | 5.61% | 12.81% | 1.55% |
EBITDA | 2,340 | 2,302 | 1,824 | 3,244 | 1,808 | 1,306 |
EBITDA Margin | 8.50% | 8.37% | 6.88% | 13.22% | 8.51% | 7.79% |
D&A For EBITDA | 264.04 | 266.52 | 276.41 | 1,448 | 218.06 | 204.62 |
EBIT | 2,076 | 2,036 | 1,547 | 1,796 | 1,590 | 1,101 |
EBIT Margin | 7.54% | 7.40% | 5.84% | 7.32% | 7.48% | 6.57% |
Effective Tax Rate | 26.34% | 26.52% | 26.85% | 24.40% | 23.72% | 22.94% |
Revenue as Reported | 27,519 | 27,502 | 26,497 | 24,531 | 21,248 | 16,759 |
Advertising Expenses | - | - | 25.49 | 30.81 | 26.27 | - |